Obagi Medical Products, Inc. Announces Publication of Study in the July Edition of the Aesthetic Surgery Journal

LONG BEACH, Calif.--(BUSINESS WIRE)--Obagi Medical Products, Inc. (Nasdaq: OMPI), a leader in topical aesthetic and therapeutic skin health systems, announced the publication of a study showing that the use of its Condition & Enhance System (also marketed as Nu-Derm), when combined with Botulinum Toxin Type A treatments (BOTOX®), provides greater improvement in overall facial appearance, as well as increased patient satisfaction, vs. BOTOX treatments with placebo. Obagi’s Condition & Enhance System is referred to as “a Hydroquinone Skin Care System Plus Tretinoin” in the report.